Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?

Antonio Rueda1*, María Casanova1, Maximino Redondo2, Elisabeth Pérez-Ruiz1 and Ángeles Medina-Pérez1

Abstract

Background: Historically, the median overall survival for follicular lymphoma (FL) has been considered to be 9-10 years, and no treatment had ever prolonged this time period. Studies conducted more than 20 years ago demonstrated that treating patients with asymptomatic FL at the onset of the disease did not increase their survival, and that almost 20% of these patients did not need any treatment in the first 10 years of follow-up. Based on these facts, most clinical practice guidelines recommend active surveillance policies for patients with asymptomatic FL.

Discussion: The introduction of anti-CD-20 monoclonal antibodies, over the last 15 years, has significantly increased the median survival rate to above 14 years. This improvement was achieved before the combination of rituximab and chemotherapy regimens became extensively used in patients with symptomatic disease. Therefore, this increase in survival may currently be more significant. At present, several clinical trials have evaluated low-toxicity therapies that prolong progression-free periods, among which rituximab monotherapy, radioimmunotherapy or the combination of rituximab with bendamustine are the most relevant. Unfortunately, these clinical trials have included only patients with symptomatic FL. The results of a recently reported clinical trial show that treatment with single-agent rituximab prolongs progression-free survival rates, time to new treatment and the quality of life of asymptomatic patients, as compared with the active surveillance strategy. Longer follow-up of these results and data regarding overall survival are awaited before this treatment can be recommended as the standard initial therapy.

Summary: There are different therapeutic possibilities for asymptomatic FL patients, but no data are currently available to indicate which option is the best. Patients need to understand the risks and benefits of observation versus treatment before a final decision can be made. For patients who want active treatment the administration of four weekly rituximab doses should be considered.

Background

Follicular lymphoma (FL) is the second most common subtype of lymphoma in Western Europe, as it represents 22-25% of non-Hodgkin’s lymphomas (NHL), according to the WHO histological classification [1,2]. The annual incidence of FL increased from two to three per 100,000 persons/year during the 1950s to five to seven per 100,000 persons/year in 2009, with a prevalence of 40 cases per 100,000 people [3].

* Correspondence: arueda@hcs.es

© 2012 Rueda et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diffuse areas containing follicles may reflect a sampling error. FL is classified into three grades according to the number of centroblasts present in the tumour tissue (Table 1). In grades 1 and 2, centrocytes prevail; in grade 3 large cells are more numerous. Grade 3 is divided into 3A (when centrocytes are still present) and 3B (characterised by the presence of solid sheets of centroblasts). Although grade 3B FL has a worse prognosis and its natural history and treatment are similar to those of DLBCL, the genetic characteristics and clinical behaviour suggest that grade 3A FL exhibits indolent behaviour very similar to that of grade 1-2 FL [5].

FL is the most common indolent lymphoma accounting for 70% of all indolent lymphomas. The treatment used for FL has been generally accepted for other less frequent indolent lymphomas. Usually the first symptom is the asymptomatic presence of enlarged peripheral nodes in the neck, and in the axillary or inguinal areas.

Occasionally, adenopathies increase and decrease in size for prolonged intervals before diagnosis. Some patients present a bulky abdominal mass not associated with urinary/intestinal obstruction. Although patients only present with one or two node areas that are clinically affected, the staging study showed dissemination affecting the spleen, liver or bone marrow in 40%, 50% and over 60% of patients, respectively. Extranodal involvement is infrequent [6].

Once a diagnosis of FL is confirmed, the pretreatment evaluation determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. Of particular importance is the information gathered from this evaluation, as it is used to determine the patient's Follicular Lymphoma International Prognostic Index (FLIPI) [7] and FLIPI 2 [8] scores, which determines whether the patient is at risk for progression (Table 2) [7,8].

Most patients are diagnosed with FL when they have an advanced stage of the disease (less than 20% present with stages I or II), although a significant percentage of patients just present with an enlarged node noted by palpation (asymptomatic FL).

FL is characterised by a chronic remission/relapse pattern. FL natural history is characterised by alternating periods of treatment, achievement of a partial/total remission, and periods free of disease and relapse or progression of the lymphoma, which requires additional treatment. With each new treatment remissions are less frequent and progression-free periods are shorter. Occasionally, partial and short spontaneous remissions can occur. Finally, patients die after developing refractory FL, FL transformation to a more aggressive lymphoma (10-70% of cases), acute toxicity, or of causes unrelated to the disease. However, FL is not necessarily an incurable disease. A randomized study with a long follow-up period, conducted in the

Table 1 Follicular lymphoma grading according to the WHO classification

| Grade | 0–15 centroblasts per hpf | >15 centroblasts per hpf |
|-------|--------------------------|-------------------------|
| 1     | 1 0–5 centroblasts per hpf| 2 6–15 centroblasts per hpf |
| 2     | 3 3A centrocytes present| 4 3B solid sheets of centroblasts |
| 3     | Follicular >75%| Follicular and diffuse 25–75% |
|       | Focally follicular <25%| Diffuse 0%** |

* hpf = high-power field of 0.159 mm².

** Diffuse areas containing >15 centroblasts per hpf are reported as DLBCL with FL (grades 1 to 2, 3A or 3B). Note that in small biopsies the absence of follicles may reflect a sampling error.

Table 2 Follicular Lymphoma International Prognostic Index (FLIPI) and Follicular Lymphoma International Prognostic Index 2 (FLIPI 2)

| FLIPI | Risk factors |
|-------|--------------|
|      |              |
| Good | Age <60 years vs. ≥60 years |
|      | Hemoglobin ≥12 g/dL vs. <12 g/dL |
|      | Serum LDH ≤ULN vs. >ULN* |
|      | Ann Arbor stage I-Ii vs. III-IV |
|      | No. of nodal sites ≤4 vs. >4 |

| Risk group | No. of factors | 5-year OS** | 10-year OS** | Relative risk |
|------------|----------------|-------------|--------------|---------------|
| Good       | 0–1            | 91%         | 71%          | 1             |
| Intermediate | 2              | 78%         | 51%          | 2.3           |
| Poor       | ≥3             | 53%         | 36%          | 4.3           |

| FLIPI 2 | Risk factors |
|---------|--------------|
|         |              |
| Low     | Beta-2-microglobulin > ULN* |
|         | Longest diameter of the largest involved node > 6 cm |
|         | Bone marrow involvement |
|         | Hemoglobin level < 12 gr/L |
|         | Age older than 60 years |

| Risk group | No. of factors | 3-year PFS*** | 5-year PFS*** | Relative risk |
|------------|----------------|--------------|--------------|---------------|
| Low        | 0              | 90.9%        | 79.5%        | 1             |
| Intermediate | 1–2           | 69.3%        | 51.2%        | 3.19          |
| High       | 3–5           | 51.3%        | 18.8%        | 5.76          |

* ULN: under limits normal.
** OS: overall survival.
*** PFS: progression free survival.
patients were not treated until the disease was progressive

With the treatments that were applied 10-15 years ago in the so-called pre-rituximab era, the median survival ranged from 9 to 10 years and no treatment was shown to increase overall survival [10]. The aim of the treatment was to improve patients’ quality of life. Therefore, asymptomatic patients were not treated until the disease was progressive (watch-and-wait strategy). Thus, patients were spared the acute and late toxic effects of the treatment.

In the past 15 years, the introduction of rituximab into the treatment of patients with FL has resulted in a significant change in the diseases’ prognosis and natural history. The median survival has increased to approximately 14 years [11], and progression-free survival periods without treatment have been extended to nearly 5 years [12]. All this has been achieved with just a slight increase in toxicity.

Unfortunately, advanced-stage FL is still incurable for the majority of patients. Thus, current therapies are aimed at achieving optimal palliation by inducing long periods of durable remissions with assumable acute and late toxicity, which limit the potential development of shared “cross-resistance” to other therapies in the future [13].

In this new setting and in the light of recent evidence, application of the “watch and wait” policy to asymptomatic patients should be reviewed.

Discussion

Definition of asymptomatic follicular lymphoma

There is not a universally accepted definition with which to identify a LF patient as being asymptomatic. The definitions available were provided in retrospective studies by cooperative groups that sought to describe clinical risk factors for disease progression. At present, the most common criteria for identifying low-risk/low-tumour burden asymptomatic patients are those established by the Groupe d’Étude des Lymphomes Folliculaires (GELF) [14,15]. According to this group, low-risk/low-tumour burden asymptomatic patients who are likely to remain untreated were those who did not meeting any of the following criteria:

- Lymph node or extranodal mass with a diameter > 7 cm
- Involvement of at least three nodal regions, each with a diameter > 3 cm
- Systemic symptoms/B-symptoms
- Splenomegaly below the umbilicus
- Compression syndrome (ureter, intestinal, orbital, and others)
- Serous pleural/peritoneal effusion (regardless of cell count)
- Leukemic expression with circulating tumour cell count > 5.0 x 10⁹ x L
- Cytopenias (concentration of granulocytes < 1.0 x 10⁹ x L and platelet count < 100 x 10⁹ x L)

These are the criteria employed in most clinical trials and recommended by the Clinical Guidelines for the Treatment of Follicular Lymphoma of the American National Comprehensive Cancer Network (NCCN) [16].

Clinical trials supporting the “watch-and-wait” strategy

Three randomized trials assessed the effectiveness of active surveillance without first-line treatment of advanced FL. The American National Cancer Institute (NCI) randomized 89 patients with advanced indolent lymphoma to “watch and wait” or to undergo aggressive combined modality treatment with prednisone, methotrexate, adriamycin, cyclophosphamide, etoposide, mechlorethamine, vincristine and procarbazine (ProMACE-MOPP), followed by total nodal irradiation (TNI) [17]. Survival in both groups at 5 years was over 75%, but progression-free survival was 51% in the chemotherapy group and 12% in the watchful waiting group.

In France, the GELF group randomized patients with advanced FL and low-tumour-burden to the watch-and-wait strategy, or to treatment with prednimustine or interferon alfa [14]. Overall survival at 5 years was similar for the three arms of the study.

The most significant study was that conducted by the British National Lymphoma Investigation Group, which randomized 309 patients with advanced indolent lymphoma (204 with FL) to immediate treatment with chlorambucil or to systemic therapy deferred until disease progression [18]. In both arms modest doses of palliative radiotherapy for the treatment of symptomatic adenopathies were permitted. With a 16-year median follow-up, the overall survival time was similar between both groups. Ten years following the initiation of the study, 19% of the patients treated with the watch and wait approach had still not required systemic therapy (40% of patients older than 70 years). However, it should be noted that the patients on immediate systemic treatment had higher response rates (63% of complete remission) than the patients who were initially untreated (27% of complete remission).

These three randomized studies revealed that 60-75% of the patients treated with the watchful-waiting protocol required treatment during the first 2-3 years of follow-up.

The situation in stage I-II follicular lymphoma, according to the Ann Arbor staging index, differs. The administration of radiotherapy (24-36 Gy) to involved nodal areas resulted in progression in 50% of the patients at 10 years [19,20]. However, when high morbidity is expected due to radiotherapy, or when the patient refuses to receive radiotherapy, watchful waiting can be a reasonable strategy. Two retrospective studies have
shown that this strategy does not affect overall survival (85% at 10 years) and, with a median follow-up period of 7.2 and 6.3 years, progression was not observed in 63% and 50% of the patients, respectively, so therapy was not required [21,22].

Active surveillance or watch and wait: Advantages and disadvantages
The watch-and-wait policy applied to asymptomatic FL patients involves more intensive surveillance than in patients in remission after first-line treatment. This is the reason why it is named “active surveillance” (or “watchful waiting”). Anticancer treatment is not administered, but surveillance visits are more frequent (every 3 months) in order to detect symptomatic progression of the disease and initiate treatment before the onset of further complications.

The advantages and disadvantages of deferring anticancer treatment in asymptomatic FL patients in the pre-rituximab era are shown in Table 3. The effectiveness of FL therapies has improved in recent years. Long remission periods are now achieved and, in certain cases, by treatments involving low acute toxicity risk. Therefore, nowadays the main disadvantage of undertaking active surveillance for indolent FL is that a treatment with a very favourable therapeutic index (efficacy/toxicity) is delayed.

What has changed in the rituximab era?
In 1997, rituximab was approved for the treatment of refractory/relapsed FL. Since then, this anti-CD-20 monoclonal antibody has proven to be effective when used as a monotherapy or in combination with chemotherapy at different stages in the FL natural history. Radioimmunootherapy and other antineoplastic agents have also demonstrated significant antitumor activity. The introduction of these drugs has modified some of the arguments on which active surveillance – as a treatment strategy in asymptomatic patients – is based.

Overall survival has increased
Historically, the median overall survival for FL was considered to be 9-10 years, and no treatment had ever prolonged this time period [10]. However, the introduction of anti-CD-20 monoclonal antibodies has significantly increased the median survival rate to above 14 years [11]. This improvement was detected before the combination of rituximab and chemotherapy regimens was extensively employed as an early treatment, and before the use of monotherapy with rituximab as a maintenance therapy after induction treatment. Both strategies have been shown to increase survival rates since 2003 [24,25]. Therefore, this increase in survival may currently be more significant.

First-line treatment with immunochemotherapy may prolong progression-free periods and the time to the next treatment
The benefit of adding rituximab to combination chemotherapy (immunochemotherapy) has been demonstrated in several randomized trials of chemotherapy with or without rituximab [26-30]. All of these trials have demonstrated improved response rates and time to progression when rituximab was added; many also showed an improvement in overall survival with rituximab.

Progression-free survival rates at 3 years were increased by approximately 15 to 30%.

An international multicenter trial randomly assigned 321 patients with previously untreated stage III/IV FL to receive eight cycles of CVP (cyclophosphamide, vincristine and prednisone) or CVP plus rituximab (R-CVP) [26]. The patients assigned to R-CVP demonstrated significantly higher rates of overall (81% versus 57%) and complete (41% versus 10%) responses. At a median follow-up period of 30 months, R-CVP improved median time to progression (32 months versus 15 months). At a median follow-up period of 53 months, the patients who received R-CVP had significantly higher rates of overall survival (83% versus 77%) [27].

In a second randomized trial, 428 patients with untreated advanced-stage FL were randomly assigned to treatment with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) with or without rituximab [28]. The patients assigned to R-CHOP had significantly superior 2-year progression-free survival rates (approximately 85% versus 65%) and overall survival rates (95% versus 90%). Another trial randomly assigned 201 patients with previously untreated stage III/IV FL to receive eight cycles of MCP (mitoxantrone, chlorambucil and prednisone) or MCP with rituximab (R-MCP) [29].
All patients who achieved a complete or partial response were treated with interferon maintenance until relapse. Overall (92% versus 75%) and complete (50% versus 25%) response rates were higher in the R-MCP treatment arm. At a median follow-up of 47 months, the patients assigned to R-MCP demonstrated superior median progression-free (not reached versus 29 months) and 4-year overall survival rates (87% versus 74%).

In a French prospective trial, 185 patients with previously untreated advanced-stage FL were randomly assigned to treatment with chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone, plus interferon) with or without rituximab [30]. After a median follow-up of 5 years, the patients assigned to chemotherapy plus rituximab group had significantly higher rates of complete response (67% versus 50%) and longer event-free survival (53% versus 37%) than those who were assigned to the chemotherapy without rituximab group.

**Low-toxicity treatments can prolong progression-free survival**

Initial treatment with single-agent rituximab appears promising given its low toxicity profile and good response rates. However, long-term follow-up of such an approach is limited. The following phase-II trials evaluated rituximab (375 mg/m² IV per week for a minimum of 4 consecutive weeks) as initial therapy in patients with FL.

In a prospective trial of single-agent rituximab in 62 chemotherapy-naive patients, most of whom had stage III or IV disease, overall response rates at 6 weeks and at maximum response were 47% and 73%, respectively, with 7% and 37% complete remissions, respectively [31]. At a median follow-up period of 30 months, median progression-free survival was 34 months. Toxicity was mostly infusion related and of brief duration.

A second trial evaluated 50 patients with stage II to IV FL and low tumour burden (no nodal or extranodal mass > 7 cm, B symptoms, splenomegaly, pleural effusion, ascites, organ compression, and elevated serum lactate dehydrogenase or beta-2-microglobulin) [32]. The overall response rate at 50 days was 73%. The median time to progression was approximately 13 months. Toxicity was minimal; the number and severity of adverse events decreased with subsequent infusions.

The North Central Cancer Treatment Group enrolled 37 patients with untreated follicular grade 1 NHL and measurable stage III/IV disease [33]. Patients received intravenous rituximab at a dose of 375 mg/m² four times weekly and no maintenance therapy was provided. The overall response rate was 72%, with 36% complete remission. The median time to progression was 2.2 years and fourteen (39%) patients remained in unmaintained remission with a median follow-up of 2.6 years.

An international trial of 202 patients with previously untreated or relapsed/refractory FL involved the administration of rituximab four times weekly [34]. The 151 patients with responding or stable disease at week 12 were randomised to no further treatment or prolonged rituximab maintenance every 2 months for four doses. At a median follow-up of 35 months, patients who received the prolonged rituximab maintenance treatment had a significantly longer median event-free-survival (23 months versus 12 months) when compared with those randomised to observation with no apparent increase in toxicity. This benefit appears to be maintained during long-term follow-up with 35% of the responders still in remission at 8 years after treatment [35]. Of note, 45% of the newly diagnosed patients in this study treated with extended-schedule rituximab were in remission at 8 years.

Anti-CD20 radioimmunoconjugates, for example ibritumomab tiuxetan and tositumomab, have demonstrated efficacy in relapsed or refractory FL. One prospective trial investigated the use of single-agent tositumomab in patients with selected low tumour burden who had had previously untreated FL. A single course of treatment with tositumomab was given to 76 previously untreated patients with FL, and resulted in overall and complete response rates of 95% and 75%, respectively, and 5-year overall survival and progression free survival rates of 89% and 59%, respectively [36].

Bendamustine plus rituximab (B-R) is a new immunomonomotherapeutic regimen with high activity and low toxicity in relapsed and refractory FL [37] that is being evaluated as a first-line therapy. In 513 patients with untreated advanced follicular, indolent and mantle-cell lymphoma, bendamustine (90 mg/m² on days 1 and 2) plus rituximab (375 mg/m² on day 1) given every 28 days for six cycles was compared with standard R-CHOP for six cycles; it also achieved statistically superior progression-free survival (54.8 months versus 34.8 months) and event-free survival (54 months versus 31 months) with less toxicity, including lower rates of grade-3 and -4 neutropenia (10.7% versus 46.5%) and leukocytopenia (12.1% versus 38.2%). Alopecia did not occur, and neuropathy was very uncommon in the B-R treated patients. There was no difference in overall survival at a median follow-up period of 32 months [38].

**Randomized clinical trials with rituximab in asymptomatic follicular lymphoma**

The large amount of information that has been generated over the last 15 years on the treatment of LF has not changed clinical opinion regarding the implementation of active surveillance in the treatment of asymptomatic LF. So far, clinical trials have only included either patients with symptomatic FL or mixed symptomatic...
and asymptomatic patients without previous stratification that would allow for separate analysis of the data obtained. In some phase II trials – such as those conducted with single-agent rituximab alone [32] or with tositumomab [36] – patients were selected with low-tumour burden using different criteria from those used in the GELF group.

The results of two randomized clinical trials including only asymptomatic LF patients conducted in the rituximab era have recently been reported. The British National Cancer Research Institute Lymphoma Group studied the effect of a low-toxicity therapy proven to be effective on asymptomatic FL patients. Their goal was to assess whether single-agent rituximab therapy significantly delayed the initiation of chemotherapy or radiotherapy, as compared with active surveillance in advanced asymptomatic FL patients according to the GELF groups’ criteria [39]. A total of 463 patients were randomised to three treatment arms:

- **Active surveillance with regular visits every 2 months**
- **Rituximab at 375 mg/m²/week for 4 weeks**
- **Rituximab at 375 mg/m²/week for 4 weeks followed by rituximab maintenance at 375 mg/m² every 2 months for two years**

During the follow-up period, painful peripheral adenopathies were not treated with radiotherapy, and the criteria for initiating a new anti-lymphoma therapy were established in the protocol. Three quarters of the patients recruited had low/intermediate risk (according to the FLIPI index). Regarding toxicity, only 10 grade 3-4 toxicity events were reported (half were infections) among the 276 patients treated with rituximab (3.5%).

Table 4 shows the response rate for each group. With a median follow-up of 32 months, 44% of the patients in the active surveillance group had initiated anti-lymphoma treatment, while the rate for the patients receiving rituximab alone was 23%; this rate was 10% for the patients treated with rituximab plus maintenance therapy. Table 5 shows disease-free survival rates and the time to next antilymphoma treatment for the three trial arms. So far, no difference has been detected in the overall survival rate (95% at 3 years). However, the following period was too short to assess this parameter.

Preliminary results from a quality of life (QOL) analysis of this trial showed that the patients who received treatment with rituximab had reduced anxiety and improved functional well-being [40]. At baseline, patient QOL scores were similar or superior to those of the general population (as assessed by the FACT-G questionnaire), with the exception of inferior emotional well-being. Although the patients treated with the “watch and wait” protocol also reported improvements in some QOL parameters, the greatest improvements in emotional and functional well-being were observed in the patients who received either rituximab maintenance therapy or monotherapy [40].

The Eastern Cooperative Oncology Group have reported the E4402 randomized phase III study (RESORT) comparing two different rituximab dosing strategies for low tumour burden FL (according to the GELF criteria) [41]. Patients received rituximab at 375 mg/m² weekly for four doses and responders were randomized to rituximab maintenance (MR) (single dose rituximab every 3 months) or rituximab retreatment (RR) (rituximab four times weekly at disease progression). Each strategy was continued until treatment failure. The primary endpoint, time to treatment failure (TTTF), was defined as progression within 6 months of last rituximab dose, no response to rituximab retreatment, initiation of alternative therapy or inability to complete protocol therapy. Secondary endpoints included time to first cytotoxic therapy, quality of life and safety.

Of 384 patients enrolled, complete or partial response was achieved in 274 (71%), who were then randomized to MR (n = 140) or RR (n = 134). With a median follow-up of 3.8 years, TTTF was 3.9 years for MR versus 3.6 years for RR (p = not significant). At 3 years, 95% of MR versus 86% of RR patients (p = 0.027) remained free of first cytotoxic therapy, but the mean number of rituximab doses per patient (including the four induction doses) was 15.8 (range 5-31) for MR and 4.5 (range 4-16) for RR. At 12 months post randomization, there was no discernible difference in health related QOL and anxiety between the two arms.

| Time of response evaluation | 7 months | 13 months | 25 months |
|----------------------------|----------|-----------|-----------|
| **Arm A (W&W)**            |          |           |           |
| + CRu                      | 3 (2%)   | 6 (3%)    | 5 (4%)    |
| PR                         | 6 (3%)   | 7 (4%)    | 5 (4%)    |
| ORR                        | 9 (5%)   | 13 (7%)   | 10 (8%)   |
| **Arm B (Rx4)**            |          |           |           |
| CR + CRu                   | 35 (43%) | 36 (44%)  | 30 (40%)  |
| PR                         | 25 (30%) | 22 (27%)  | 10 (13%)  |
| ORR                        | 60 (73%) | 58 (71%)  | 40 (53%)  |
| **Arm C (Rx4RM)**          |          |           |           |
| CR + CRu                   | 100 (54%)| 122 (67%) | 98 (70%)  |
| PR                         | 61 (33%) | 36 (20%)  | 12 (9%)   |
| ORR                        | 161 (87%)| 158 (87%) | 110 (79%) |

| W&W: watch and wait; Rx4: rituximab four weekly doses; Rx4 + RM: rituximab four weekly doses plus rituximab maintenance; CR: complete response; CRu: undetermined complete response; PR: partial response; ORR: overall response rate. | p value (Arm B vs Arm C) | p = 0.0216 | p = 0.0077 | p < 0.0001 |
Table 5 Progression-free survival and time to next antilymphoma treatment in the rituximab versus “watch-and-wait” study

|                | PNRNT 3 years | Differences between arms | HR p value | PFS 3 years | Differences between arms | HR p value |
|----------------|---------------|--------------------------|------------|-------------|--------------------------|------------|
| W&W            | 48%           | Rx4 vs W&W               | 0.37 p < 0.001 | 33%         | Rx4 vs W&W               | 0.46 p < 0.001 |
| Rx4            | 80%           | Rx4 + RM vs W&W          | 0.20 p < 0.001 | 60%         | Rx4 + RM vs W&W          | 0.21 p < 0.001 |
| Rx4 + RM       | 91%           | Rx4 + RM vs Rx4          | 0.57 p = 0.10 | 81%         | Rx4 + RM vs Rx4          | 0.43 p < 0.001 |

PNRNT: patients not receiving next therapy; PFS: progression free survival; HR: hazard ratio; W&W: watch and wait; Rx4: four weekly doses of rituximab; Rx4 + RM: four weekly doses of rituximab plus rituximab maintenance.

Summary

The active surveillance therapy strategy in asymptomatic FL patients is based on the disease’s natural history and on the results of trials conducted many years ago. Such trials included patients with different histologic types of asymptomatic lymphoma (based on classifications that are no longer used). Similarly, the treatments used in the past were less effective and more toxic than those used today.

At present, new low-toxicity therapies that prolong progression-free periods and time to new antilymphoma therapy are available, among which rituximab monotherapy (with or without maintenance), radioimmunotherapy or the combination of rituximab with bendamustine are the most relevant. Unfortunately, the impact of current therapies on asymptomatic FL patients is still unclear, as only one specific clinical trial has been conducted in this population.

The results of a recently reported clinical trial [39] show that treatment with single-agent rituximab prolongs progression-free survival rates, time to new treatment and the quality of life, as compared with the active surveillance strategy applied to asymptomatic FL patients. However, we do not know if “progression-free survival” or the “time to next treatment” (the main endpoint of the study) are the best end points to decide which option is better in this patient population. It is obvious that patients treated with rituximab will have a superior response rate and longer time to the next treatment than those who were just observed. The critical point is what is going to happen after the next treatment (first-line treatment for observed patients; second-line for the other patients) and, ultimately, with the overall survival of the patients. Furthermore, there is some concern regarding the fact that patients relapsing after rituximab induction plus 2-year maintenance treatment could be particularly resistant to standard immunochemotherapy. Longer-term follow-up of these results is awaited before this treatment can be recommended as the standard initial therapy.

So, it is time to leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients? Not yet but we are getting closer through effective and less toxic treatments. In this clinical scenario the initial discussion with the patient is typically a long one. Patients need to understand the entire situation of the disease and the risks and benefits of observation versus treatment. The physician must also look at the entire patient, other comorbidities, the patient’s mindset and other factors before a final decision can be made. For patients who want active treatment the administration of four weekly rituximab doses should be considered. However, the administration of rituximab maintenance should be avoided until further data based on longer follow-up periods are available.

Competing interests
Antonio Rueda MD, PhD has received research grant support from Roche and Celgene. María Casanova MD, Maximino Redondo MD, PhD, Elisabeth Pérez-Ruiz MD and Ángeles Medina-Pérez MD have no significant financial interest to disclose.

Authors’ contributions
Antonio Rueda was responsible for the conception and design of the study, and the acquisition, interpretation and analysis of data. María Casanova was also responsible for the design of the study and carried out analysis of data. María Casanova, Maximino Redondo and Elisabeth Pérez-Ruiz contributed to the interpretation of data. Ángeles Medina-Pérez contributed to the conception and design of the study and interpretation of data. All authors read and approved the final manuscript.

Author details
1Department of Oncology, Hospital Costa del Sol, Marbella, Spain.
2Biochemistry, Hospital Costa del Sol, Marbella, Spain.

Received: 5 December 2011 Accepted: 14 May 2012
Published: 31 May 2012

References
1. Harris NL, Swerdlow SH, Jaffe ES, et al. Follicular lymphoma. In WHO classification of tumours of haematopoietic and lymphoid tissues. Edited by Swerdlow SH, Campo E, Harris NL, Es Jaffe, Piriell SA, Stein H, Thiele J, Vardoman JW, Lyon: IARC; 2008:226–229.
2. Dreyling M: Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 4:119–120.
3. Cancer incidence in Five Continents, Volume X. Edited by Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, Lyon, France: International Agency for Research on Cancer Scientific Publications n° 160; 2006.
4. Ngan BY, Chen-Levy Z, Weiss LM, et al: Expression in non-Hodgkin’s lymphoma of the bcl-2 protein associated with the t(14,18) chromosomal translocation. N Engl J Med 1988, 318:1638–1644.
5. Bosq-Bouvier AG, van der Berg A, Haralambea E, et al: Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol 2006, 37:528–533.
6. Fernández de la Rueda C, Martinez-Pozo A, Mercadal S, et al: Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. Br J Haematol 2011, 153:334.
7. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:783–789.
8. Federico M, Belfer M, Marcheselli L, et al. Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 2009; 27:4555–4562.
9. Peterson BS, Petroni GR, Frizola G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the Cancer and Leukemia Group B. J Clin Oncol 2003; 21:15–25.
10. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993; 20:57–88.
11. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23:8447–8452.
12. Czuczman MS, Weaver R, Alkuzweny B, Berflein J, Grillo-Lopez AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22:4711–4716.
13. Czuczman MS. Controversies in follicular lymphoma: "What, When, Where, and Why?" (Not necessarily in that order). Hematol Am Soc Hematol Educ Program 2006; 1:301–310.
14. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol 1997; 15:1101–1117.
15. Solal-Celigny P, Lepage E, Brousses N, et al. Doxorubicin-containing regimen with o without interferon alfa-2b for advanced follicular lymphoma: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol 1999; 16:2332–2338.
16. Zelenetz AD, Abramson JS, Advani RH, et al. Risk and clinical implications of rituximab maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Natl Compr Canc Netw 2011; 9:494–560.
17. Young RC, Latchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:4261–4267.
18. Arndtshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362:516–522.
19. McCaulpin P, Fuller LM, Velasquez WS, et al. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58:1596–1602.
20. Guadagnoli BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2005; 64:926–934.
21. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22:1454–1459.
22. Soubyran Y, Eghbal H, Trajani M, et al: Is there any place for a wait-and-see policy in stage I follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol 1996; 7:713–718.
23. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25:2426–2433.
24. Schulz H, Bohlius JF, Treille S, et al. Immunootherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706–714.
25. Van Ders MH, Van Glabbeke M, Giurea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853–2858.
26. Marcus R, Imre K, Belach A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417–23.
27. Marcus R, Imre K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579–4586.
28. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725–3732.
29. Herold M, Haas A, Snock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study. J Clin Oncol 2007; 25:1985–1992.
30. Salle S, Mounier N, de Guilbert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824–4831.
31. Hairwood JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:4261–4267.
32. Colombat P, Salle S, Brousses N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101–108.
33. Witzig T, Yukav AM, Habermann TH, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23:1103–1108.
34. Ghelmini M, Schmitz SF, Ciglati S, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4461–4462.
35. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4840–4848.
36. Karnsins MS, Tsuck M, Etes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352:441–449.
37. Robinson KH, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-Cell and mantle cell Non-Hodgkin’s Lymphoma. J Clin Oncol 2008; 26:4473–4479.
38. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114:468. abst405.
39. Arndtshna KM, Smith P, Qian W, et al. An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis. Blood 2010, 116abstract 6. ASH Annual Meeting Abstracts.
40. Arndtshna KM, Qian W, Stephens R, et al. Preliminary results of quality of life (QoL) analyses from the Intergroup Phase III randomised trial of rituximab vs a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma. Ann Oncol 2011; 22(Suppl 4)abstract 019. 019.
41. Kahl BS, Hong F, Williams ME, et al. Results of Eastern Cooperative Oncology Group protocol E4402 (REORTE): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011, 118abstract 6. ASH Annual Meeting Abstract.

doi:10.1186/1471-2407-12-210
Cite this article as: Rueda et al.: Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients? BMC Cancer 2012 12:210.